Showing results (111-120 of 121) with videos related to
Sort By:
Pageof 13
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|October 21, 2022
Schisandrin B protects against LPS-induced inflammatory lung injury by targeting MyD88Weiwei Zhu, Wu Luo, Jibo Han, et al.Bioorganic Chemistry|February 23, 2024
Discovery of a doublecortin-like kinase 1 inhibitor to prevent inflammatory responses in acute lung injuryBinhao Cai, Ying Xu, Ruixiang Luo, et al.Journal of Medicinal Chemistry|May 9, 2024
Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory DiseasesLingfeng Chen, Ruixiang Luo, Lin Ma, et al.Journal of Medicinal Chemistry|May 2, 2023
Design, Synthesis, and Bioevaluation of Novel MyD88 Inhibitor c17 against Acute Lung Injury Derived from the Virtual ScreenPan Chen, Ying Zhou, Xiaobo Li, et al.European Journal of Medicinal Chemistry|April 6, 2023
Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatmentRuixiang Luo, Weitao Fu, Jingjing Shao, et al.European Journal of Medicinal Chemistry|March 24, 2023
Novel O-benzylcinnamic acid derivative L26 treats acute lung injury in mice by MD-2Xiang Li, Lina Yin, Jing Liao, et al.Journal of Medicinal Chemistry|December 7, 2024
Discovery of Novel MyD88 Inhibitor A5S to Alleviate Acute Lung Injury with Favorable Drug-like PropertiesPan Chen, Yu Zou, Xiemin Wang, et al.The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2025
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 StudyRoy S Herbst, Byoung Chul Cho, Caicun Zhou, et al.The Lancet. Oncology|October 24, 2023
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Do-Youn Oh, Patricio Yañez, et al.Pageof 13